Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04249778 · ClinicalTrials.gov registry record · Phase 4
Dapagliflozin at Discharge on Hospital Heart Failure Readmission
A Phase 4 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 4
- Development phase
- 105
- Enrollment target
NCT04249778 is a Phase 4 study that has completed, run by Emory University. The registered enrollment target is 105 participants.
The verdict
NCT04249778, a Phase 4 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 105 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of dapagliflozin treatment in preventing hospital re-admissions, emergency room (ER) visits, urgent clinic visits, and death in patients with and without type 2 diabetes (T2D) after hospital admission for heart failure.
Interventions
- DRUG Placebo
- DRUG Dapagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2020-07-29 |
| Est. Completion | 2022-03-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04249778
The ClinicalTrials.gov registry entry for NCT04249778 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04249778 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04249778 about?
NCT04249778 is a clinical study titled "Dapagliflozin at Discharge on Hospital Heart Failure Readmission". This study will evaluate the safety and efficacy of dapagliflozin treatment in preventing hospital re-admissions, emergency room (ER) visits, urgent clinic visits, and death in patients with and without type 2 diabetes (T2D) after hospital admission for heart failure.
What is the current status of trial NCT04249778?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 105 participants. The study started on 2020-07-29. Estimated completion is 2022-03-03.
What interventions are being tested in trial NCT04249778?
The interventions under investigation include: Placebo (DRUG), Dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT04249778?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.